Aktienanalyse zu Becton Dickinson and Co (BDX)BDXBecton Dickinson and Co

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Becton Dickinson (BDX) is a good buy right now due to its current price of $189.52, which is below the average analyst price target of $204, indicating potential upside. Additionally, the company reported a strong Q3 2026 earnings with a revenue of $5 billion, reflecting a year-over-year increase of 4.4%. However, a risk to consider is the recent dip in net income for Q2 2026, which was -311 million USD, highlighting some volatility in earnings.

15 analysts cover BDX: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 192.64.